Lindahl acted as legal advisor to Corline Biomedical
Through the agreement, Imperative Care is given the exclusive right to use CHS™ in all types of neurovascular products given a certain level of compensation. Corline undertakes to supply CHS™-coated products according to defined specifications, but also to assist in further development and market registration of the current product. In addition, Corline will participate in the development of additional CHS™-coated products within the indication area. These products have the potential to generate revenue for Corline of approximately SEK 150 million per year and a total of more than SEK 1 billion.
Lindahl's team consisted of Hugo Norlén and Erika Svensson.
Corline's press release (in Swedish) is available here.
Do you want to know more? Contact:
Hugo Norlén
Partner | AdvokatErika Svensson
Partner | AdvokatCarousel items
-
Cases and transactions
6/3/2026
Lindahl advises the majority shareholder on the sale of Herok Group
Lindahl has advised the majority shareholder of Herok Group in connection with HLL Hyreslandslaget's acquisition of all shares in the company.
-
Portraits
6/2/2026
Björn on M&A at Lindahl: "No two deals are alike"
Björn Andersson on M&A at Lindahl: how each transaction brings new challenges – and why no two deals are alike. Read about his experience and approach.
-
News articles
5/27/2026
Inside Silicon Valhalla – unicorns, AI and the battle for the future of work
Lindahl's partner Ottilia Boström moderated the panel "AI in the Land of Unicorns" at the Nordic Employment Summit in Stockholm – with representatives from Legora, Altor, Klarna and Ericsson on how AI is reshaping the future of work.
-
Knowledge
5/26/2026
The clock is ticking for the retail sector and new licensing requirements
On 20 November 2026, new consumer credit legislation comes into force, introducing licensing requirements for retailers, car dealers and other ancillary credit providers. Find out what it means for your business.
-
Read more news and insights?
